The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

EDITORIAL

Data from real-world registries: can it guide development of the bioresorbable scaffolds of tomorrow?

EuroIntervention 2017;13:1259-1262. DOI: 10.4244/EIJV13I11A197

1. Cardiovascular Institute, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; 2. Cardialysis BV, Rotterdam, the Netherlands


Bioresorbable scaffolds (BRS) were conceived and introduced into clinical practice with the objective of overcoming the limitations of newer-generation drug-eluting stents (DES), such as the risk of target lesion revascularisation and device thrombosis1. The drug-eluting poly-L-lactide acid-based bioresorbable vascular scaffold (BVS; Abbott Vascular, Santa Clara, CA, USA) was the first to be introduced onto the market in 2011, claiming late lumen enlargement and restoration of normal vasomotor response as potential advantages related to its transient scaffolding. These data were based on the first-in-man experience, which was the only evidence available at that time2,3.

In 2015, the Gauging coronary Healing with ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Sorting out coronary stents, as time goes by

Latest news